Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
LUND, SWEDEN / ACCESSWIRE / June 13, 2023 / BioInvent International (STO:BINV) Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the study design and status, and summarizes the early clinical results generated so far in...
One additional patient has developed a partial response (PR) and one patient has remained on stable disease for over 80 weeks These long-lasting responses in hard-to-treat metastatic diseases, in patients who had previously progressed after treatment with anti-PD1/PDL1 agents, strongly suggest...
LUND, SE / ACCESSWIRE / June 5, 2023 / BioInvent International (STO:BINV) ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it will present the comp...
LUND, SWEDEN / ACCESSWIRE / June 2, 2023 / BioInvent International (STO:BINV) A differentiated -agonist- approach from BI-1808, the first-in-class antibody currently in phase 1 clinical development Phase 1/2a study of BI-1910 as single agent and in combination with pembrolizumab Explora...
LUND, SE / ACCESSWIRE / May 25, 2023 / BioInvent International (STO:BINV) Treatment of all Phase 1a cohorts in monotherapy completed with no safety concerns Stabilization of injected lesions in 11/18 patients An independent Safety Review Committee has approved initiation of the combinat...
LUND, SWEDEN / ACCESSWIRE / May 23, 2023 / BioInvent International (STO:BINV) Experienced regulatory affairs leader who has worked on all stages of product development Will play important role in progress of pipeline of four assets in five clinical trials Lund, Sweden - May 23, 2023 -...
LUND, SWEDEN / ACCESSWIRE / April 27, 2023 / BioInvent International (STO:BINV) The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to elect Erik Esveld as new Board member, to re-elect the Board members Natalie Berner, Kristoffer Bisse...
LUND, SE / ACCESSWIRE / April 26, 2023 / BioInvent International (STO:BINV) "After the end of the quarter, we received very positive news in our BI-1206 project. We now have a fourth complete response in the ongoing Phase 1/2 trial with BI-1206 in combination with rituximab in non-Hodgkin's ly...
Reinforcing previous results and adding up to a total of four complete responses in the intravenous (IV) arm of the study Recruitment continues in the subcutaneous (SC) arm of the study; first data to be reported H1 2023 New patent granted in Japan relating to treatment of relapsed/refr...
LUND, SWEDEN / ACCESSWIRE / April 6, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today a...
News, Short Squeeze, Breakout and More Instantly...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China Nat...
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development...